Will producing less help to balance the market? Only if peers follow suit.
Investors looking to inject growth into their portfolios should give these companies a closer look.
The pharma company reported fourth-quarter and full-year 2018 operating results.
The company announced an update after meeting the FDA.
The nursing home operator's fourth-quarter losses and tepid outlook disappointed investors.
A rival's setback is this small cap's gain, right?
The titanium dioxide manufacturer announced progress on its proposed acquisition of Cristal.
Most investors have probably never heard of this small-cap laboratory equipment supplier, but it reached an important inflection point in 2018.
The company secured a deal paving the way to commercialize a generic version of the former best-selling drug in the world.
An important phase 3 clinical trial enrolled its last patient at the beginning of the year, which means top-line results could be right around the corner.
The gene-editing pioneer announced a new regulatory designation for its lead drug candidate.
The company reported preliminary full-year 2018 results and set expectations for a solid year of growth in 2019.
The company's lead drug candidate got thrown into a whirlwind of uncertainty.
Two well-managed renewable energy businesses are not getting much love from Wall Street right now, but the high-yield stocks are great long-term buys.
The pharma company reported positive results from an important phase 3 trial.
The paper company recovered after an awful December and then proved Wall Street wrong with full-year 2018 operating results.
One of America's largest electric utilities has committed to generating all of its electricity from zero-carbon sources by 2050. Will peers follow?
Wall Street soured on this water utility after it announced a massive acquisition in a new industry, but that could change when full-year 2018 earnings are reported.
The group rebounded after a terrible end to 2018, but each has big plans for the year ahead.
Also, never buy a penny stock.